Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Effects of Saccharomyces boulardii on Gut Microbiota in IBS-D
ChiCTR2500115213Phase 4Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of piromidic acid in Diarrhea-predominant irritable bowel syndrome (IBS-D), sponsored by Union Hospital. Primary endpoint: Gut microbiota changes and maintenance duration after Saccharomyces boulardii. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
piromidic acid
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on ChiCTR2500115213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115213.